Sun Pharma Signs MFN Pricing Agreement with US Medicaid Program

Sun Pharmaceutical Industries has reached an agreement with the United States administration that has significant implications not just for the company, but for the Indian pharmaceutical industry as a whole. The agreement includes the extension of Most Favoured Nation (MFN) pricing to US state Medicaid programmes and future innovative medicine launches.

Under this framework, the US aims to provide drug prices for Medicaid—its government-funded health insurance for low-income citizens—that are competitive with the lowest prices found in other developed nations. In exchange for this concession, Sun Pharma will benefit from an extension of more than two years before Section 232 tariffs will affect its innovative pharmaceutical products.

While specific commercial terms of this agreement remain undisclosed, its impact is expected to reshape the dynamics of Sun Pharma's operations in the US. The company has evolved from being primarily an Indian exporter of generic medicines to a major player in high-value pharmaceuticals, particularly in dermatology, immunology, oncology, and ophthalmology. Currently, the US market accounts for approximately 27% of Sun's global revenue and is its primary market for innovative medicines.

Earlier this year, Sun Pharma also announced its acquisition of US-based Organon for an enterprise value of $11.75 billion, which increases its portfolio in branded medicines, women's health products, and biosimilars. This acquisition significantly enhances Sun’s long-term positioning within the American healthcare landscape.

The MFN pricing agreement introduces a potential challenge, as it necessitates that medicines supplied through Medicaid be offered at lower prices than what the market might typically demand. Shrikant Akolkar, a seasoned pharma analyst at Nuvama Institutional Equities, noted that sales through Medicaid could be characterised as a “low margin proposal,” despite the advantages of accessing a larger patient base. Thus, Sun Pharma faces a delicate balance: accepting pricing pressures in certain market segments in return for greater patient access and reduced tariff risks.

Analyst Salil Kallianpur highlighted the importance of this agreement in the broader context of the Organon acquisition. He suggested that the deal could offer “policy certainty” as Sun Pharma integrates the new entity and strengthens its presence in America. This is particularly relevant as the US government aims to lower medication costs while simultaneously seeking to reduce pharmaceutical manufacturing reliance on foreign countries.

The Section 232 measures are part of a larger strategy aimed at addressing concerns regarding the US’s dependency on imported pharmaceuticals and the active pharmaceutical ingredients that constitute them. Under current guidelines, companies that enter into qualifying MFN and onshoring arrangements may enjoy preferential tariff treatment, although generics remain exempt from these tariffs.

This distinction is crucial for India, which supplies around 47% of generic prescriptions in the US, with pharmaceutical exports to the US amounting to about $8.7 billion in the fiscal year 2023-24. Traditionally, Indian pharmaceutical firms have operated on a straightforward business model: produce medicines cost-effectively in India and export them to the US, one of the largest healthcare markets globally.

However, this formula is now evolving. The key takeaway from Sun's agreement is that mere cost competitiveness may not suffice for success in the evolving US market. The US is increasingly focused on the origins of medicine production and the reliability of supply chains. Recent statements from the White House indicate that the nine companies participating in the latest agreements are collectively committed to investing at least $19.6 billion in US-based manufacturing.

For Indian pharmaceutical companies, this presents both challenges and opportunities. While relocating production to the US may erode some of the cost advantages enjoyed in India, it also opens the door for a dual manufacturing model where India serves as the base for research and large-scale production, while US facilities focus on local manufacturing and supply needs.

As Sun Pharma adapts to this new landscape, its operations in the US now encompass manufacturing, sales, marketing, clinical development, and both active ingredients and finished products. The company's existing commitment to the US market underscores its status as a critical case study for the Indian pharmaceutical sector.

With the potential implications of the Organon acquisition and greater US presence, Sun Pharma's strategy may serve as a model for how other Indian pharmaceutical companies adapt their own operations in response to similar pressures. For larger firms with substantial exposure to the American market, considerations will likely include local manufacturing, acquisitions, and partnerships against the backdrop of maintaining the cost benefits of existing operations in India.

Should Indian pharmaceutical companies manage to enhance their presence in the US without relinquishing their robust manufacturing capabilities in India, the country could continue to serve as a major hub for global pharmaceutical production and supply chains. However, there remains an inherent risk that increasing high-value manufacturing could gradually shift overseas.

Thus, Sun Pharma’s recent agreement should not merely be viewed as an isolated deal between the company and the US administration, but rather as a reflection of broader transformations occurring in the world’s largest pharmaceutical market.